PT ES Get the brief

Medulloblastoma Intelligence Hub

Navigating Medulloblastoma,
Together.

Most common malignant brain tumor in children, medulloblastoma represents ~20% of pediatric CNS tumors. This platform was built to make clinical trial information accessible to every patient and caregiver.

Read the Medulloblastoma Guide Explore the research

Free forever · Written for patients & families · No medical jargon

Live research field · updated hourly

157Studies tracked

2,500Sources monitored

24/7Live analysis

ClinicalTrials.gov, PubMed, the FDA and thousands of medical sources — read continuously, scored for Medulloblastoma relevance.

Where would you like to start?

Everything you need, in one place

Tools and information for everyone navigating Medulloblastoma — from a clear diagnosis guide to the very latest research.

Understanding Medulloblastoma

A clear guide to medulloblastomas, treatments, and what to expect.

Read the Medulloblastoma Guide

Research & publications

Curated trials, molecular data, and research trends for medulloblastoma.

Browse publications

Clinical trials

Explore active trials by condition, location, and treatment type.

Search trials

Continuously classified · relevance-scored

How we work

How we keep you informed

We read thousands of global medical sources around the clock, analyse new studies as they emerge, and translate the complex ones into clear, everyday language — so what matters reaches you without the noise.

We monitor

Continuously scanning ClinicalTrials.gov, PubMed, the FDA and thousands of sources for new Medulloblastoma-relevant research.

We analyse

Every study is classified, scored for relevance, and enriched with molecular markers and treatment data.

You discover

Browse an intelligence dashboard, explore active trials, or read a curated brief — all in clear, everyday language.

Why Zyntha

The information exists.
Now it’s yours.

We use technology to accelerate clinical trials efficiently, bring new treatments to patients faster, and work toward improving outcomes for every medulloblastoma patient.

Built specifically for the Medulloblastoma community — every study written for patients and families, updated within hours.

Why this platform

What makes this different

Written without the jargon

Every study, trial, and article is summarised so patients and families can actually understand it.

Updated continuously

Running 24/7 across thousands of sources. New trials and publications appear within hours — not weeks.

Designed for Medulloblastoma

Built for one community. Every feature — from molecular markers to subtype filters — speaks your language.

Trusted sources

Sourced from the world’s leading institutions

All content comes from peer-reviewed journals, verified trial registries, and top cancer research centres.

ClinicalTrials.govPubMedThe Lancet OncologyNature MedicineFDANCINeuro-OncologyASCOMD AndersonDana-FarberMemorial Sloan KetteringJAMA +108 more

Every article is scored for medulloblastoma relevance, classified by WHO grading criteria, and summarized in patient-friendly language before it reaches you.

We are not medical professionals. This platform is for educational and research purposes only — always consult your healthcare team for treatment decisions.

Navigating Medulloblastoma,Together.